Angiex Raises $31 Million to Advance First-in-Class Nuclear-Delivered ADC AGX101 Through Phase 1 Trial
核心洞察
Angiex Inc. (搜索) completed $31 million in financing to advance AGX101, a first-in-class TM4SF1 (搜索)-directed Nuclear-Delivered Antibody-Drug Conjugate, through Phase 1 dose escalation in advanced solid tumors (搜索).
The company's novel ND-ADC technology delivers therapeutic payloads directly into the nucleus of tumor cells, potentially enhancing efficacy and therapeutic margin compared to conventional ADCs.
The ongoing Phase 1 trial is evaluating doses up to 10 mg/kg in an all-comers solid tumor population to determine maximum tolerated dose and assess safety, tolerability, and preliminary anti-tumor activity.
Cambridge-based biotech Angiex Inc. (搜索) announced the completion of $31 million in financing to advance its lead Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) AGX101 through the dose-escalation portion of its Phase 1 clinical trial in patients with advanced solid tumors (搜索). The financing included participation from both new and existing investors, with Paulson Investment Company (搜索), LLC serving as placement agent for a $16 million equity offering.
Novel Nuclear Delivery Technology
AGX101 represents a first-in-class TM4SF1 (搜索)-directed ND-ADC that utilizes Angiex's proprietary nuclear delivery mechanism. Unlike conventional ADCs, the company's ND-ADC platform releases therapeutic payloads directly into the nucleus of cells within the tumor environment. According to Angiex, this direct nuclear delivery approach holds promise for enhancing both the efficacy and therapeutic margin of traditional antibody-drug conjugates.
"Angiex is very pleased with the strong investor support the company has received from both insiders and new investors, and we are grateful for their support of our shared mission," said Paul Jaminet, Ph.D., Angiex's founder and chief executive officer. "In addition to progressing AGX101 through key endpoints of the Phase 1 clinical trial, these funds enable Angiex to refine its development strategy by further evaluating AGX101 in selected tumor types and in combination with immune checkpoint inhibitors."
Phase 1 Trial Design and Objectives
The ongoing Phase 1 study is an open-label, dose-escalation and expansion trial designed to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of AGX101 monotherapy. The dose escalation portion evaluates doses up to 10 mg/kg in an all-comers solid tumor patient population with the primary goal of determining a maximum tolerated dose.
Following dose escalation, the expansion portion of the study will evaluate safety and efficacy of treatment at the Recommended Phase 2 Dose across multiple indications. The trial can be tracked at clinicaltrials.gov under study ID NCT06440005.
Company Background and Mission
Angiex Inc. (搜索) is a privately held biotechnology company founded by scientific experts in angiogenesis, vascular biology, and oncology. The company's mission centers on exploiting newly discovered biological transport mechanisms to develop drugs with enhanced anti-cancer (搜索) activity. Beyond AGX101, Angiex is developing a broader portfolio of ND-ADCs designed to address high unmet medical needs in oncology.
The company's approach builds on the premise that direct nuclear delivery of therapeutic payloads can overcome limitations of conventional ADC technologies, potentially offering improved therapeutic outcomes for cancer (搜索) patients with limited treatment options.